Background: After the success of the CAPRISA-004 clinical trial showing efficacy of vaginally-applied tenofovir (TFV)-based gels at preventing HIV infection, rectal formulations are currently being explored as a prevention option. However, further research is needed to characterize the safety of rectal microbicide gels. Standard mucosal safety tests, such as inflammatory cytokine measurements, may miss important immunological or biological side effects. Advances in systems biology tools, such as mass spectrometry, allow the monitoring of hundreds of mucosal immune factors simultaneously. Here we performed a comprehensive proteomic analysis to explore the impact of tenofovir 1% gel when applied rectally in the Project GEL study (MTN).
Methods: Project GEL was a phase 1 randomized, double-blind, multi-site, placebo- controlled trial in which in which 24 participants were randomized 1:1 to receive rectal tenofovir 1% gel or (HEC) universal placebo gel. Study participants received one dose at first visit under observation, and then after a one-week recovery period, seven consecutive once-daily doses. Rectal mucosal swabs were collected on each visit. Mucosal samples were then analyzed by label-free tandem-mass spectrometry. Data was normalized and log transformed, followed by statistical analysis including paired (time-effects) and unpaired (across study arm) t-tests to identify differentially expressed proteins. Only high power (low technical variance) proteins were utilized in downstream analysis.
Results: Over 249 unique proteins were identified in rectal mucosal samples. Within the TFV-arm, 7% (17/249, p<0.05) and 10% of total proteins changed (25/249, p<0.05) after 1 and 8 daily applications of TFV-gel, respectively, compared to 3% (7/249, p<0.05) and 6% (16/249,p<0.05) in the HEC arm. Biofunctional analysis utilizing DAVID gene ontology toolset indicated the TFV arm differentially expressed proteins were strongly associated with epidermal development (p=5.1E-9) and structural activity functions (p=1.5E-07), whereas HEC arm had milder associations with cell activation (p=4.3E-3) after 7 days usage.
Conclusions: These preliminary studies suggest that rectal TFV-gel usage may be associated with mucosal proteome changes related to epidermal development. Further long-term studies are warranted for validation of these biomarkers including the impact of TFV-based rectal microbicide gels on the overall mucosal proteome.